Clinical trial · no report yet · Phase 2
COXEN
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- NCT02177695 ↗
- Completed
- SWOG Cancer Research Network
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 7 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine; Cisplatin; Methotrexate; Vinblastine; Doxorubicin; Filgrastim
- Arms
- Gemcitabine & Cisplatin · Experimental
- Dose Dense MVAC · Experimental
- Enrollment
- 237
- Primary outcomes
- Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate
- Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate
- Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC
- Correlation Between GC-and ddMVAC-COXEN Score
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Aug 28, 2014
- Primary completion
- Feb 2020
- Results posted
- Yes
- Registry record
- NCT02177695 · updated Sep 19, 2024
Publications
linked from the registry- Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson IM, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks JJ, Choi W, Dinney CPN, Elemento O, Lerner SP, McConkey DJ, Faltas BM, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. NPJ Digit Med. 2025 Mar 22;8(1):174. doi: 10.1038/s41746-025-01560-y. PubMed 40121304
- Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr, Lerner SP. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 Sep;84(3):341-347. doi: 10.1016/j.eururo.2023.06.014. Epub 2023 Jul 4. PubMed 37414705
- Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 May 1;27(9):2435-2441. doi: 10.1158/1078-0432.CCR-20-2409. Epub 2021 Feb 10. PubMed 33568346